Real-world use of cenobamate in pediatric focal epilepsies and developmental epileptic encephalopathies: A multicenter retrospective series.

Fecha de publicación: Fecha Ahead of Print:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Soto-Insuga V
  • Valls Carbó A
  • Pinzón-Acevedo AG
  • González-Alguacil E
  • Peñas JJG
  • Jamardo AS
  • Aznar-Laín G
  • Ibáñez-Micó S
  • Martínez HA
  • Buenache R
  • Rekarte S
  • Olivera AP
  • Tuero-Montiel E
  • DomínguezCarral J
  • López M
  • Ribes AG
  • González MJM
  • Arias E
  • Ron AG
  • Boronat S
  • Viñas ET
  • Casellas D
  • Navarro V
  • Conejo D
  • Miravet E
  • Román IS
  • Nagel-Rein AG
  • Cabeza MM
  • Aledo-Serrano Á

Abstract

OBJECTIVE: Cenobamate (CNB) is an anti-seizure medication approved for focal-onset seizures in adults, with growing evidence supporting its use in pediatric drug-resistant epilepsy (DRE). This study evaluates the efficacy, retention, and safety of CNB in children and adolescents, including those with developmental and epileptic encephalopathies (DEEs). METHODS: We conducted a retrospective, multicenter study of 169 pediatric patients (0-18 years) with DRE treated with CNB across centers in Spain. Seizure response (=50% reduction) and seizure freedom (no seizures in the previous month) were assessed at 3, 6, and 12 months. RESULTS: At 12 months, CNB showed a retention rate of 89.2%, with 83.9% of patients achieving seizure response and 19.6% reaching seizure freedom. Response rates were 73.4% at 3 months and 77.1% at 6 months, with seizure freedom increasing from 11.8% at 3 months to 21.1% at 6 months. Outcomes were comparable between DEEs and focal epilepsies, indicating broad-spectrum efficacy. Seizure worsening occurred in 4.7% of patients, all with DEEs. After adjusting for seizure type, those patients with focal seizures had higher odds of achieving seizure response (odds ratio [OR] 95% confidence interval [95% CI] 5.46, 1.27-23.52; p = 0.02) and seizure freedom (OR 95% CI 5.32, 1.57-17.97; p < 0.01). Median CNB doses (mg/kg/day) were 1.78 (range 0.37-12.5), 2.5 (range 0.67-12.5), and 3.19 (range 0.96-9.09) at 3, 6, and 12 months, respectively. Adverse events occurred in 44.9% of patients, most commonly somnolence (42.3%) and dizziness (22.4%), which improved with slower titration. SIGNIFICANCE: CNB appears effective and well-tolerated in pediatric DRE, including DEE, with high retention and sustained efficacy over time. Adverse events were generally manageable with dose adjustments, and slow, weight-based titration improved tolerability. Prospective studies are warranted to confirm these findings.

© 2025 International League Against Epilepsy.

Datos de la publicación

ISSN/ISSNe:
0013-9580, 1528-1167

EPILEPSIA  WILEY

Tipo:
Article
Páginas:
4712-4724
PubMed:
40736694
Enlace a otro recurso:
www.scopus.com
Factor de Impacto:
1,893 SCImago ℠
Cuartil:
Q1 SCImago ℠

Citas Recibidas en Web of Science: 8

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • antiseizure medications; cenobamate; developmental and epileptic encephalopathies; focal seizures; pediatric epilepsy

Cita

Compartir